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A B S T R A C T
Purpose
Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best
to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL
(Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis)
was a multicenter breast cancer study integrating clinical, imaging, and genomic data to evaluate pathologic
response, RFS, and their relationship and predictability based on tumor biomarkers.
Patients and Methods
Eligible patients had tumors  3 cm and received neoadjuvant chemotherapy. We determined
associations between pathologic complete response (pCR; defined as the absence of invasive
cancer in breast and nodes) and RFS, overall and within receptor subsets.
Results
In 221 evaluable patients (median tumor size, 6.0 cm; median age, 49 years; 91% classified as poor risk on
the basis of the 70-gene prognosis profile), 41% were hormone receptor (HR) negative, and 31% were
human epidermal growth factor receptor 2 (HER2) positive. For 190 patients treated without neoadjuvant
trastuzumab, pCR was highest for HR-negative/HER2-positive patients (45%) and lowest for HR-
positive/HER2-negative patients (9%). Achieving pCR predicted favorable RFS. For 172 patients
treated without trastuzumab, the hazard ratio for RFS of pCR versus no pCR was 0.29 (95% CI, 0.07
to 0.82). pCR was more predictive of RFS by multivariate analysis when subtype was taken into
account, and point estimates of hazard ratios within the HR-positive/HER2-negative (hazard ratio, 0.00;
95% CI, 0.00 to 0.93), HR-negative/HER2-negative (hazard ratio, 0.25; 95% CI, 0.04 to 0.97), and
HER2-positive (hazard ratio, 0.14; 95% CI, 0.01 to 1.0) subtypes are lower. Ki67 further improved the
prediction of pCR within subsets.
Conclusion
In this biologically high-risk group, pCR differs by receptor subset. pCR is more highly predictive
of RFS within every established receptor subset than overall, demonstrating that the extent of
outcome advantage conferred by pCR is specific to tumor biology.
J Clin Oncol 30:3242-3249. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Advances in adjuvant therapy as well as screening
have helped reduce breast cancer mortality,1 but
approximately 20% of patients with breast cancer in
the United States still die of their disease.2 Mortality
is highest among women who present with larger,
palpable tumors3 and in whom the absolute inci-
dence has not decreased much.4 Thus, better treat-
ments are needed.
Breast cancer is a heterogeneous disease that
varies widely in outcomes and response to standard
therapies.5,6 Neoadjuvant or preoperative chem-
otherapy yields outcomes equivalent to adjuvant
therapy7,8 but has the benefit of downstaging tu-
mors and increasing breast conservation rates,9
and it permits assessment of individual tumor
response to treatment.7-10
The I-SPY 1 TRIAL (Investigation of Serial
Studies to Predict Your Therapeutic Response With
Imaging and Molecular Analysis) is a multicenter
neoadjuvant breast cancer study designed to estab-
lish standards for collecting molecular and imaging
data over the course of care. Primary objectives were
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to evaluate whether response to therapy—as measured by imaging
(magnetic resonance imaging [MRI] volume) response and patho-
logic complete response (pCR)—would predict recurrence-free survival
(RFS), overall and within biologic and imaging subsets. Secondary objec-
tives were to develop a resource of clinical, molecular, genetic, and
imaging biomarker data and a multicenter network to support high-
quality real-time biomarker evaluation for future trials of tailored
therapy. This first report describes the ability of short-term response to
therapy, as measured by pCR, to predict RFS, both overall and within
receptor subsets.
PATIENTS AND METHODS
The I-SPY 1 TRIAL was a collaboration of the American College of Radiology
Imaging Network (ACRIN), Cancer and Leukemia Group B (CALGB), and
the National Cancer Institute (NCI)’s Specialized Programs of Research Excel-
lence (SPORE). It consisted of two protocols developed to identify markers of
response to conventional neoadjuvant chemotherapy: CALGB 150007 (mo-
lecular marker component) and ACRIN 6657/CALGB 150012 (imaging com-
ponent). The protocol (schema is shown in Fig 1) was approved by institutional
review boards at all participating institutions. Patients signed one combined in-
formed consent form before joining the study, which allowed them to simultane-
ously enroll onto the CALGB and ACRIN protocols. Details of accrual have been
published previously.10a
The primary end point for the trial was RFS according to the STEEP
(Standardization of Events and End Points) criteria.11 RFS was calculated from
the date of chemotherapy initiation. An estimated target sample size of 244
patients with 15% drop rate was needed to be able to detect (with 90% power
and 0.05 type I error) a hazard ratio of 0.5 between two biomarker-defined
groups (eg, MRI volume change in response to neoadjuvant chemotherapy or
risk groups defined by molecular signatures). Defining the relationship of
biomarkers to RFS were secondary aims of the trial. All sites tested for estrogen
receptor (ER) status, progesterone receptor (PR) status, and human epidermal
growth factor receptor 2 (HER2) overexpression and assessed pCR. pCR was
defined as the absence of invasive tumor in both breast and axillary lymph
nodes after neoadjuvant therapy.
Patient Eligibility
Eligible patients had histologically confirmed invasive breast cancers
measuring at least 3 cm by clinical examination or imaging, with no evidence
of distant metastatic disease, and were candidates for neoadjuvant chemother-
apy with an anthracycline-based regimen. Patients with T4 or inflammatory
disease were eligible. Patients were considered evaluable if they completed
neoadjuvant chemotherapy.
Study Treatment and Procedures
After four cycles of anthracycline-based therapy, patients could either
undergo surgical excision or receive a taxane before surgery. Treatment after
surgery, including chemotherapy, radiation, and hormone therapy, was at the
physician’s discretion.
Biopsies and imaging studies were conducted at four time points
during neoadjuvant chemotherapy (Fig 1). Details of the imaging compo-
nent (ACRIN 6657/CALGB 150012) are described elsewhere.12 Trastu-
zumab treatment was not dictated by the protocol and was not used as
neoadjuvant therapy until April 2005.
Standard Clinical Biomarkers
Hormone receptor (HR) status (ER positive or PR positive) and HER2
overexpression were measured from diagnostic samples obtained by a stan-
dard method in Clinical Laboratory Improvement Amendments (CLIA)
–approved laboratories at local sites on formalin-fixed, paraffin-embedded
core biopsies obtained at diagnosis.
Both ER and PR status were determined by immunohistochemistry
(IHC) and were considered positive if the Allred score was  313; HER2
status was determined by IHC and/or fluorescent in situ hybridization
assays locally and centrally at the University of North Carolina.14 HER2
status was regarded as positive if there was 3 staining and/or fluorescent
in situ hybridization positivity (positive defined as HER2/CEP17 ratio
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Fig 1. I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) schema. Sixteen-gauge core-needle
biopsies were performed at four time points: T1, before treatment; T2, between 24 and 96 hours after starting treatment; T3, after completing the regimen that
contained doxorubicin (if a taxane was to be given); and T4, at the time of surgical resection. Blood was drawn to obtain serum and plasma before chemotherapy,
between anthracycline and taxane regimens, if applicable, and before surgery. Magnetic resonance (MR) images were obtained before chemotherapy, approximately
2 weeks after the first dose of anthracycline, at the end of anthracycline treatment (if the patient went on to receive a taxane), and again before surgical resection. The
goal of the trial was to relate early and late outcomes. Early outcome measures included MR volume change and rates of pathologic complete response (pCR). Late
outcomes were measured by recurrence-free survival (RFS), which was measured as the proportion of patients who did not experience an invasive breast cancer
recurrence in the ipsilateral breast or regional nodes, distant organ sites, or death from any cause for the specified time period. MRI, magnetic resonance imaging. (*)
Twenty-four to 96 hours after the start of anthracycline. (†) Two weeks after the start of anthracycline.
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Ki67 IHC staining was performed centrally at the University of North
Carolina by using standard avidin-biotin complex technique.15 Tumors were
categorized as low, intermediate, or high proliferation index for less than 10%,
10% to 25%, and more than 25% of tumor cell nuclei staining positive,
respectively, and were interpreted by a single pathologist (C.L.). Molecular
assays and analyses are described in detail elsewhere.10a
Data Collection and Platform Integration for Analysis
The NCI Center for Bioinformatics developed a Web-based system,
caINTEGRATOR, to support centralized reporting of results across disparate
sources and platforms17 and provided a common platform for accessing data
(https://caintegrator-stage.nci.nih.gov/ispy/index2.jsp). I-SPY 1 data dated
February 2011 was used for the analyses in this article.
Statistical Analysis
Rates of pCR were calculated for each combination of HR and HER2
status. Kaplan-Meier survival curves were generated for patients who achieved
pCR versus those who did not, overall and within each receptor subset. The
RFS hazard ratios and P values for comparisons of patients who achieved pCR
versus those who did not were based on multivariate Cox proportional hazards
models, adjusting for age and clinical stage. These analyses were conducted by
using JMP Version 8.0.1 (SAS Institute, Cary, NC).
RESULTS
Patients
Between May 2002 and March 2006, 237 patients were enrolled.
Figure 1 shows the protocol schema; Figure 2 shows the number of
patients accrued and reasons for exclusions. The remaining 221 pa-
tients received neoadjuvant chemotherapy and were evaluable. Of
these, 215 (97%) underwent surgical resection and had pCR informa-
tion available (Fig 2). HER2 and HR information was available for 210
of the 215 patients (HER2 status was missing for four, and HR infor-
mation was missing for one).
The characteristics of patients who participated in the trial are
provided in Table 1. Average baseline tumor size was 6.0 cm (range, 0
to 25 cm) clinically and 6.8 cm (range, 0 to 18.4 cm) by MRI. Most
patients (65%) had clinically or pathologically confirmed axillary
lymph node involvement at diagnosis; 90% had tumors of intermedi-
ate or high histologic grade. Overall, 59% of patients were HR positive
(n  131), and 31% were HER2 positive (n  67); 29% (n  55) were
scored as Ki67 low, 33% (n  63) as Ki67 medium, and 38% (n  71)
as Ki67 high.
All patients received doxorubicin plus cyclophosphamide as ini-
tial chemotherapy (54% on a dose-dense [every 2 weeks] schedule,
34% on a standard [every 3 weeks] schedule, and 12% on a modified
schedule), and 95% subsequently received a taxane (55%, every 2
weeks; 26%, every 3 weeks; and 19%, once per week). Among the 66
patients with HER2-positive tumors, 46 (69%) were treated before
trastuzumab was approved for adjuvant breast cancer in 2005 and
therefore did not receive concurrent neoadjuvant trastuzumab. Of the
46 HER2-positive patients who did not receive neoadjuvant trastu-
zumab, 17 HER2-positive patients (36%) received adjuvant trastu-
zumab (plus one HER2-negative patient). A total of 172 received the
same chemotherapy regimen without any trastuzumab (Fig 2). The
median follow-up time was 3.9 years (range 3.0 to 7.5 years).
Tumor Receptors and Rates of pCR
Of the 210 patients with receptor status and surgery results, 56
(27%) experienced a pCR. Of the 190 patients who did not receive
neoadjuvant trastuzumab, 44 (23%) experienced a pCR. The pCR rate
was lowest (9%) in the HR-positive/HER2-negative receptor subset
and highest (45%) in the HR-negative/HER2-positive receptor subset.
The incremental effect of being HR negative versus HR positive re-
sulted in an estimated 24% increase in the rate of pCR; the incremental
increase in the likelihood of pCR in HER2-positive versus HER2-
negative patients was 21% (Table 2).
The impact of Ki67 is best appreciated within the receptor sub-
sets. Ki67 staining was available for 166 of the 190 patients who did not
receive neoadjuvant trastuzumab (Table 3). The pCR rate was signif-
icantly higher within the high Ki67 group (34% v 11% in the low/
medium group) overall, and Ki67 remained a significant predictor of
pCR when HR and HER2 status were taken into account (multivariate
logistic regression P  .02). When the impact of Ki67 on pCR was
assessed within receptor subsets (Table 3), high Ki67 was significantly
associated with increased responsiveness only in the HER2-negative
subsets. In addition, the incremental impact of HER2 positivity on
pCR rate was observed only within the low/medium Ki67 (31%) but
not the high Ki67 (7%) subset. These findings suggest that adding
Ki67 to standard receptor subtyping may further improve the predic-
tion of pCR.
Relationship of pCR to RFS
RFS for all patients (excluding those treated with trastuzumab)
and the receptor subsets are shown in Figure 3, stratified by whether a
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Fig 2. I-SPY 1 (Investigation of Serial Studies to Predict Your Therapeutic
Response With Imaging and Molecular Analysis) CONSORT diagram. Of the 237
patients enrolled, 221 patients were evaluable, 215 had pathology results, and
210 had receptor data available. HER2, human epidermal growth factor receptor;
HR, hormone receptor. (*) No. of patients who did not receive neoadjuvant
trastuzumab. Trastuzumab was approved for use during the last year of study
enrollment and was available to HER2-positive patients after that time. (†) No. of
patients who did not receive any trastuzumab.
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hazard ratios, confidence intervals, and absolute difference between 3-
and 5-year survival on the basis of achieving pCR versus not achieving
pCR. For the 172 patients treated without neoadjuvant or adjuvant
trastuzumab, the hazard ratio for RFS of pCR versus no pCR was 0.29
(95% CI, 0.07 to 0.82; P  .02). pCR is more highly predictive of RFS
when the three established receptor categories—HR positive/HER2
negative, triple negative, and HER2 positive—are added to the multi-
variate model, with a hazard ratio of 0.18 (95% CI, 0.04 to 0.53;
P  .001). Given the potential confounding of results by nonrandom-
ized use of trastuzumab, Figure 3 shows patients with HER2-positive
tumors who did not receive trastuzumab as neoadjuvant (n  20) or
as adjuvant (n  17) therapy. Since the total sample size was small, the
HER2-positive patients are shown as a combination of the entire
HER2-positive subset, both HR positive and HR negative (Fig 3). The
RFS curves by pCR in Figure 3 (right side) show that when partition-
ing a population into the three biomarker subsets, each of the three














Premenopausal 106 48 82 48
Race
White 165 75 133 77
African American 42 19 28 16
Asian 9 4 6 3
Other 5 2 5 3
Clinical tumor size, cm
Median 6.0 6.0
Range 0-25 0-18




Clinically node positive at diagnosis 143 65 107 62
Histologic grade (baseline)
Low 18 8 15 9
Intermediate 96 43 76 44
High 103 47 78 45
Indeterminate 4 2 3 2
Clinical stage (baseline)
I‡ 3 1 3 2
IIA 43 19 39 23
IIB 61 28 46 27
IIIA 78 35 59 35
IIIB 11 5 11 6
IIIC 7 3 4 2
Inflammatory 17 8 9 5
Indeterminate 1  1 1  1
Hormone receptors (baseline)
ER positive 125 57 104 60
PR positive 104 47 88 51
HR positive (ER or PR) 131 59 109 63
HER2 positive (baseline) 67 30 29 17
HR negative/HER2 negative (baseline;
triple negative) 53 24 52 30
Neoadjuvant treatment
Anthracycline only 11 5 11 6
Anthracycline  taxane 187 85 159 92
Anthracycline  taxane  trastuzumab 20 9 0 0
Anthracycline  taxane other 3 1 2 1
Surgery type
Mastectomy 123 56 96 56
Lumpectomy 92 41 77 45
No surgery 6 3 0 0
Postoperative adjuvant therapy
Any hormonal therapy 128 58 108 63
Tamoxifen 75 34 67 39
Aromatase inhibitor 95 43 79 46
Ovarian suppression 20 9 15 9
Ovarian ablation 7 3 6 3
Trastuzumab 35 16 0 0
(continued in next column)










No. % No. %
Ki67
Negative 8 4 8 5
Low 47 21 37 22
Intermediate 63 29 48 28
High 71 32 57 33
Indeterminate 32 14 22 13
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor
receptor 2; HR, hormone receptor; I-SPY 1 TRIAL, Investigation of Serial
Studies to Predict Your Therapeutic Response With Imaging and Molecular
Analysis; MRI, magnetic resonance imaging; PR, progesterone receptor.
Of the 221 evaluable patients, 215 had surgical excision, as shown in the
CONSORT diagram (Fig 2).
†Patient subset with pathology assessment, known receptor status, and
without any trastuzumab treatment.
‡After the data lock for this analysis, it was determined that two of the three
patients designated as stage I had clinical stage II disease.
Table 2. Rates of pCR by Receptor Subset for Patients Who Did Not Receive
Neoadjuvant Trastuzumab (n  190)
Receptor
Subset
HR Positive HR Negative Overall
No. pCR/No. % No. pCR/No. % No. pCR/No. %
HER2 status
Positive 8/24 33 10/22 45 18/46 39
Negative 8/93 9 18/51 35 26/144 18
Overall 16/117 14 28/73 38 44/190 23
NOTE. Rates of pCR are shown for the receptor subsets and include patients
for whom pathologic evaluation and receptor status were available and
exclude the 20 patients who received trastuzumab as neoadjuvant therapy.
The Overall (%) column shows that being HR negative v HR positive results in
a 24% higher probability of achieving a pCR (P  .01). The bottom row
(Overall) shows that being HER2 positive v HER2 negative results in a 21%
higher probability of achieving a pCR (P  .01). Overall data appear in bold.
Abbreviations: HER2, human epidermal growth factor receptor 2; HR,
hormone receptor; pCR, pathologic complete response.
*For the 20 patients who received neoadjuvant trastuzumab, the pCR rate
was 60%. These 20 patients are not included in the table.
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estimated hazard ratios is smaller than the overall hazard ratio (eg,
0.00, 0.25, 0.14 are all less than 0.29). This is an instance of Simpson’s
paradox.18 However, the parameters of which these are estimates are
not precisely known and so they may not have the same relationships.
DISCUSSION
The I-SPY 1 population had clinical and biologic high-risk features: me-
dian age 49 years, 41% HR negative, 90% intermediate or high grade, and
91% high risk by the 70-gene profile.10a For patients with biologically
high-risk invasive breast cancers, 3-year RFS is better for those who expe-
rience a pCR after neoadjuvant chemotherapy than for those who do not.
The observation of Simpson’s paradox based on the estimated
hazard ratios in Figure 3 is associated with well-known characteristics
of breast cancer. Of the three tumor subtypes in Figure 3, the tumors
that are least sensitive to either adjuvant or neoadjuvant chemo-
therapy are those that are HR positive/HER2 negative.5,19,20 How-
ever, these tumors have the best prognosis in the absence of
chemotherapy. Despite the fact that these tumors have the lowest
rate of pCR (9% v 36% and 41%), patients with these tumors tend
to have a better RFS than patients with triple-negative or HER2-
positive tumors, both overall and within pCR and no pCR categories.
So although our relatively small study is not sufficient by itself to
conclude that the population parameters have the same relationship as
their estimates, this observation is consistent with what we understand
about the biology of breast cancer and is to be expected. Other re-
searchers should categorize tumors by molecular and receptor char-
acteristics in relating pCR and longer-term end points such as RFS and
overall survival.
These results provide additional insights into previous neoadju-
vant trials that have examined the relationship between pCR and
RFS.21 For example, although most neoadjuvant chemotherapy trials
have shown that pCR is associated with favorable outcome, this was
not seen in the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-27 neoadjuvant trial. In that trial, although pCR im-
proved significantly when paclitaxel was added to a doxorubicin-
based chemotherapy regimen, the improvement was not of the same
magnitude as that for RFS or overall survival.7 The possibility of a
Simpson’s paradox relationship suggests that analyzing only overall
pCR and survival rates may have underestimated the true predictive
effect of pCR in NSABP B-27.
The rate of pCR in the HR-positive/HER2-positive subset was
lower than in the HR-negative/HER2-positive subset in the I-SPY
TRIAL (in the absence of neoadjuvant trastuzumab). The sample
sizes in our study were small, but this effect has also been observed
consistently in three large randomized phase III neoadjuvant trials:
NeoALTTO (Neoadjuvant Lapatinib or Trastuzumab Optimiza-
tion Study),22 GeparQuinto,23 and NEOSPHERE (Neoadjuvant
Study of Pertuzumab and Herceptin in an Early Regimen Evalua-
tion)24; the effect was less than that mentioned in a personal
communication with G. von Minckwitz on August 19, 2011, and
more than that mentioned in the CHER-LOB (Preoperative Che-
motherapy Plus Trastuzumab, Lapatinib or Both in HER2-Positive
Operable Breast Cancer) phase II trial.25 In the nonrandomized
MD Anderson Cancer Center neoadjuvant series,26 pCR rates were
also lower in the HR-positive/HER2-positive subset than in the HR-
negative/HER2-positive subset, and the subsequent RFS rates were
also lower in this group. Our trial results are limited by the small
number of patients who received neoadjuvant trastuzumab. Ongoing
and future trials will help us better understand whether different
treatment approaches will be needed to improve outcome for HER2-
positive disease on the basis of HR status.
High rates of proliferation, as measured by Ki67, increased the
likelihood of pCR. However, Ki67 is highly correlated with receptor
subsets and appears to improve the ability to predict response within
all subsets except HER2 positive.
Clinical trials for breast cancer have historically contained a mix of
receptor subsets. Given our findings and those of others that tumor biol-
ogy is different for these subsets, comparisons should be anchored within
molecular subsets rather than across whole trial populations. Sufficiently
powered analyses of subsets on the basis of receptor status or molecular
profiles (which are highly correlated with receptor status) should be a
planned feature of future trials if we hope to extract the maximal value
fromthem.10a Molecularprofilesatbaselinemayprovidetheopportunity
to identify, beyond HR positivity alone, patients likely to have a good
survival outcome as shown by I-SPY 1 molecular analyses.10a
Getting a drug approved for marketing is estimated to take
more than 10 years and $1 billion.27,28 To shorten the period of
time for drug development (what has been referred to as knowl-
edge turns29), a new approach is needed. The neoadjuvant ap-
proach gives us the opportunity to use response to therapy as an
early evaluation end point. Fortunately, whether chemotherapy is
Table 3. Rates of pCR Within Ki67 Classes Stratified by Receptor Status
Receptor
Subset
Ki67 Low/Medium (n  105) Ki67 High (n  61)
HR Positive HR Negative Overall HR Positive HR Negative Overall
No. % No. % No. % No. % No. % No. %
HER2 status
Positive 4/12 33 4/10 40 8/22 36 1/7 14 4/10 40 5/17 29
Negative 2/67 3 2/16 13 4/83 5 3/15 20 13/29 45 16/44 36
Overall 6/79 8 6/26 23 12/105 11 4/22 18 17/39 44 21/61 34
NOTE. Rates of pCR are shown for the receptor subsets, which were further stratified by Ki67 dichotomized as low/medium v high. High Ki67 includes patients
with  25% of tumor cells staining positive for Ki67. For the low/medium Ki67 group, the Overall (%) column shows that the incremental effect of HR negative over
HR positive is 15%, and the incremental effect of HER2 positive over HER2 negative is 31% (2 test P  .05 for both). For the high Ki67 group, the Overall (%)
column shows that the incremental effect of HR negative over HR positive is 26% (2 test P  .05), and the incremental effect of HER2 positive over HER2 negative
is 7%. Overall data appear in bold.
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor; pCR, pathologic complete response.
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given before surgery or after does not influence RFS and overall
survival,30 but giving chemotherapy before surgery offers an op-
portunity both to evaluate response to therapy and to alter subse-
quent treatment if the tumor is downstaged.9 More importantly, it
informs us about the success of standard and experimental therapies.
For example, in the MD Anderson Cancer Center neoadjuvant trial, in
which HER2-positive patients were randomly assigned to receive pac-
litaxel followed by fluorouracil, epirubicin, and cyclophosphamide
plus or minus trastuzumab, the significant increase in pCR in the
trastuzumab arm31 (65.2% v 26% for patients who did not receive
trastuzumab) in just 34 patients foreshadowed the results of the adju-
vant trastuzumab trials, which accrued more than 9,000 patients and
were completed 1 year later.32,33 Several trials are now evaluating novel
agents in the neoadjuvant setting, including poly (ADP-ribose) poly-
merase inhibitors, CALGB 40601, NEOSPHERE, and GeparQuinto.
Our results support this approach and further emphasize that evalua-
tion should be performed by receptor or molecular subset.
Despite optimal therapy, many patients still remain at substantial
risk for disease progression. To make more rapid progress in finding
agents that may reduce risk for these women, we have incorporated
the observations from I-SPY 1 TRIAL into the design of the I-SPY 2
TRIAL. That trial uses pCR as an end point and focuses on women
with biologically higher risk disease—in the context of either standard
marker subsets or molecular subsets of breast cancer—and uses an
adaptive design to screen phase II agents in combination with the
taxane portion of chemotherapy.34 The goal is to test these novel
agents for their ability to improve pCR rates for 10 subsets of breast
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Fig 3. Recurrence-free survival strati-
fied by pathologic complete response
(pCR) for the overall population (left side)
of patients (excluding all patients treated
with trastuzumab; n  38) and (right side)
by hormone receptor (HR) –positive/
human epidermal growth factor receptor 2
(HER2) –negative, HR-negative/HER2-
negative (triple negative), and HER2-
positive subsets.
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focusing on high-risk patients and analyzing data by subsets, the
neoadjuvant setting can provide a unique opportunity to acceler-
ate learning.
In an effort to develop a noninvasive measure of pCR, I-SPY 1
also included multiple imaging parameters12 and demonstrated that
change in MR volume is the imaging marker that best predicts pCR,
has the potential to serve as a noninvasive measure of response to
therapy, and may further accelerate evaluation of novel agents in
combination with standard treatments. In I-SPY 2, MR volume is
being used to provide information about response to chemotherapy
between regimens, information that cannot otherwise be obtained
without surgical resection.
The conclusions of our study are limited by the short follow-up
time. It is well known that the HR-positive patients remain at risk for
recurrence for many years, and early recurrence data may not reflect
the overall outcome. However, the Oxford Overview Analysis36 of
early breast cancer trials strongly suggests that the benefit of chemo-
therapy is reflected by the distant disease-free survival at 5 years; that is,
the survival curves diverge during the first 5 years, but after year 5, they
are parallel, suggesting that the survival benefit from chemotherapy is
likely to be manifest in the first 5 years. With the median follow-up for
the I-SPY 1 TRIAL currently at 3.9 years, current rates of RFS are likely
to reflect primarily the benefit from chemotherapy.
The outcome for patients in I-SPY 1 is also affected by hormonal
therapy given adjuvantly, although molecular predictors of sensitivity
to endocrine therapy have been described and will likely further refine
our ability to focus on patients most at risk for disease progression at
the time of diagnosis.37,38
In conclusion, the I-SPY 1 TRIAL shows that the ability of pCR to
predict outcome is substantially improved when analyzed within tu-
mor subsets. This predictive power is sufficiently strong that pCR can
be used as an early indicator of RFS. Indeed, pCR is the primary end
point of the next generation study, the I-SPY 2 TRIAL, which is
designed to identify agents early in the drug development cycle that
improve the rates of pCR and for which molecular subsets this is so.
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